Amplicore Revenue and Competitors
Estimated Revenue & Valuation
- Amplicore's estimated annual revenue is currently $804k per year.
- Amplicore's estimated revenue per employee is $100,500
- Amplicore's total funding is $20.7M.
Employee Data
- Amplicore has 8 Employees.
- Amplicore grew their employee count by -27% last year.
Amplicore Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.5M | 5 | -17% | N/A | N/A |
#2 | $8.4M | 42 | 8% | N/A | N/A |
#3 | $12.9M | 64 | 0% | N/A | N/A |
#4 | $3.6M | 18 | -25% | N/A | N/A |
#5 | $1090M | 5838 | 8% | $38.4M | N/A |
#6 | $5.8M | 29 | -3% | N/A | N/A |
#7 | $0.8M | 8 | -27% | $20.7M | N/A |
#8 | $13.7M | 68 | 6% | N/A | N/A |
#9 | $0.8M | 8 | 60% | $67.6M | N/A |
#10 | $25.9M | 129 | -21% | N/A | N/A |
What Is Amplicore?
We develop injectable therapeutics for degenerative musculoskeletal disorders to serve unmet medical needs. Unlike current treatments, we take a regenerative approach to joint osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tear. We are committed to addressing the underlying causes of joint discomfort, in addition to relieving pain. Our mission is to translate scientific innovation into effective but minimally invasive products that can be easily delivered to patients.
keywords:N/A
$20.7M
Total Funding
8
Number of Employees
$804k
Revenue (est)
-27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Amplicore News
Amplicore plans to begin a first clinical trial in 2022 for its solution to treat acute meniscal tears, one of the most common knee injuries.
Amplicore Inc., a Cincinnati, OH-based early-stage biopharmaceutical company, closed its $4m seed round of funding. The round was led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital. Led by Dr. Chia-Ying (James) Lin, ...
CINCINNATI, March 25, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at $4 million. Investme ...
Other Companies in Mason
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 8 | -20% | N/A |
#2 | $1M | 11 | 10% | N/A |
#3 | $1.7M | 11 | -8% | N/A |
#4 | $1.9M | 13 | -24% | N/A |
#5 | $2M | 16 | N/A | N/A |